Federal officials approved the release of genetically modified
mosquitoes on Friday for field trials in the Florida Keys. The decision
comes as the number of Zika cases transmitted by the mosquitoes rises.
The release of genetically modified mosquitoes in the Florida Keys
cleared a significant hurdle Friday when the U.S. Food and Drug
Administration announced they pose no significant environmental danger.
The preliminary findings, to be published in the Federal Register, will be open for public comment for the next 30 days. But the initial federal review likely clears the way for a long-delayed field trial by British producer Oxitec in the tiny affluent neighborhood of Key Haven a mile east of Key West.
Pressure has mounted to speed up testing after the arrival of the Zika virus, which is carried by the Aedes aegypti mosquito, in the U.S. and Florida. While no cases have been contracted locally, health officials fear South Florida could face an outbreak. Oxitec’s genetically modified mosquitoes have already been released in South America, where health officials say an ongoing Zika outbreak could infect 4 million people by the end of the year. The virus is tied to a host of health problems and may be the cause of a spike in babies born with microcephaly in Brazil.
Oxitec CEO Hadyn Parry welcomed the move in a statement.
“The Aedes aegypti mosquito represents a significant threat to human health, and in many countries has been spreading Zika, dengue and chikungunya viruses,” he said. “This mosquito is non-native to the US and difficult to control, with the best available methods only able to reduce the population by up to 50%, which is simply not enough.”
But some residents in the Keys, backed by opponents of the genetic modification industry, have fought bitterly to stop the release, mounting a petition that collected 160,000 signatures.
Pitched as a safer, more affordable way of battling Oxitec’s modified male mosquitoes are engineered to produce offspring with a kill-switch, or defective gene that kills them. The offspring also bear a florescent marker gene so larvae can be identified when inspectors conduct mosquito counts and gauge the progress of the program.
Critics, however, say no tests have linked the release of mosquitoes to a reduction in disease and worry there are unknown consequences.
Comments can be submitted online or mailed to The Division of Dockets Management, HFA-305, Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852.
The preliminary findings, to be published in the Federal Register, will be open for public comment for the next 30 days. But the initial federal review likely clears the way for a long-delayed field trial by British producer Oxitec in the tiny affluent neighborhood of Key Haven a mile east of Key West.
Pressure has mounted to speed up testing after the arrival of the Zika virus, which is carried by the Aedes aegypti mosquito, in the U.S. and Florida. While no cases have been contracted locally, health officials fear South Florida could face an outbreak. Oxitec’s genetically modified mosquitoes have already been released in South America, where health officials say an ongoing Zika outbreak could infect 4 million people by the end of the year. The virus is tied to a host of health problems and may be the cause of a spike in babies born with microcephaly in Brazil.
Oxitec CEO Hadyn Parry welcomed the move in a statement.
“The Aedes aegypti mosquito represents a significant threat to human health, and in many countries has been spreading Zika, dengue and chikungunya viruses,” he said. “This mosquito is non-native to the US and difficult to control, with the best available methods only able to reduce the population by up to 50%, which is simply not enough.”
But some residents in the Keys, backed by opponents of the genetic modification industry, have fought bitterly to stop the release, mounting a petition that collected 160,000 signatures.
Pitched as a safer, more affordable way of battling Oxitec’s modified male mosquitoes are engineered to produce offspring with a kill-switch, or defective gene that kills them. The offspring also bear a florescent marker gene so larvae can be identified when inspectors conduct mosquito counts and gauge the progress of the program.
Critics, however, say no tests have linked the release of mosquitoes to a reduction in disease and worry there are unknown consequences.
Comments can be submitted online or mailed to The Division of Dockets Management, HFA-305, Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852.
No comments:
Post a Comment